By Mill Chart
Last update: Jan 18, 2024
Our stock screener has singled out GENMAB A/S -SP ADR (NASDAQ:GMAB) as an attractive growth opportunity. NASDAQ:GMAB is demonstrating remarkable growth potential while maintaining strong financial indicators, making it a reasonably priced option. We'll explore this further.
ChartMill assigns a Growth Rating to every stock. This score ranges from 0 to 10 and evaluates the different growth aspects like EPS and Revenue, both in the past as in the future. NASDAQ:GMAB scores a 7 out of 10:
ChartMill employs its own Valuation Rating system for all stocks. This score, ranging from 0 to 10, is determined by evaluating different valuation factors, including price to earnings and free cash flow, both in absolute terms and relative to the market and industry. NASDAQ:GMAB has earned a 5 for valuation:
ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of NASDAQ:GMAB, the assigned 8 reflects its health status:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:GMAB has achieved a 7:
More Affordable Growth stocks can be found in our Affordable Growth screener.
Check the latest full fundamental report of GMAB for a complete fundamental analysis.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
GENMAB A/S -SP ADR
NASDAQ:GMAB (4/26/2024, 7:00:00 PM)
After market: 28.15 0 (0%)28.15
+0.69 (+2.51%)
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
Genmab is buying a privately held company focused on antibody drug conjugates.
Genmab (GMAB) and AbbVie (ABBV) win FDA priority review for a marketing application to expand the label for their bispecific antibody epcoritamab-bysp. Read more here.
BMO has upgraded Genmab (GMAB) to outperform, stating that it was “incrementally more confident” in the company’s ability to diversify its business longer term
Genmab reports a FY operating profit of DKK 5,321 million in 2023, with revenue reaching DKK 16.47B, driven by successful collaborations and strong product...